Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B

REGENERON PHARMACEUTICALS, INC.

2021-FY EPS reported $71.97 revenue$16,071,700,000

EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).
REGEN-COV FY2021 U.S. net product sales ~$5.82B; Q4 sales ~$2.29B.
Provided corporate update at J.P. Morgan conference; highlighted pipeline progress including Aflibercept 8mg Ph3 data expected 2H22.
Dupixent annualizing at ~$6.6B run rate; three potential new Ph3 indications in 2022 (CSU, PN, EoE).
Announced $3B share repurchase program in Nov 2021; over $7.5B repurchased since Nov 2019.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.